LSTA
Lisata Therapeutics, Inc.NASDAQHealthcare$5.02-0.40%ClosedMarket Cap: $45.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.92
P/S
265.66
EV/EBITDA
-1.65
DCF Value
$1.90
FCF Yield
-35.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-10711.2%
Net Margin
-9756.5%
ROE
-84.4%
ROA
-93.5%
ROIC
-117.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $100.0K | 85.0% | $-3.1M | $-3.0M | $-0.33 | — |
| FY 2025 | $170.0K | 14.1% | $-18.2M | $-16.6M | $-1.91 | — |
| Q3 2025 | $0.00 | NaN% | $-4.4M | $-4.2M | $-0.49 | — |
| Q2 2025 | $70.0K | 100.0% | $-4.9M | $-4.7M | $-0.54 | — |
| Q1 2025 | $0.00 | NaN% | $-5.8M | $-4.7M | $-0.55 | — |
| Q4 2024 | $1.0M | 100.0% | $-4.9M | $-4.6M | $-0.55 | — |
| FY 2024 | $1.0M | 100.0% | $-22.4M | $-20.0M | $-2.40 | — |
| Q3 2024 | $0.00 | NaN% | $-5.3M | $-4.9M | $-0.59 | — |
| Q2 2024 | $0.00 | NaN% | $-5.5M | $-5.0M | $-0.61 | — |
| Q1 2024 | $0.00 | NaN% | $-6.6M | $-5.4M | $-0.65 | — |
| Q4 2023 | $0.00 | NaN% | $-6.0M | $-5.4M | $-0.66 | — |
| FY 2023 | $0.00 | NaN% | $-25.7M | $-20.8M | $-2.58 | — |